TB a respiratory disease that is preventable and treatable yet kills more than 1.4 million people every year is chronically underfunded, with diagnosis and treatment failing to reach millions. AP/File
JOHANNESBURG: A new tuberculosis treatment that slashes costs and the pill burden for patients will be rolled out in five high-incidence countries this year, international medical research body the Aurum Institute said on Wednesday.
TB a respiratory disease that is preventable and treatable yet kills more than 1.4 million people every year is chronically underfunded, with diagnosis and treatment failing to reach millions.
It is currently the world’s deadliest infectious disease, with progress to stop its spread unwound by the Covid-19 pandemic as restricted movement disrupted treatment.
Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said it has signed a pact with the Clinton Health Access Initiative (CHAI) to expand access to life-saving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership. The partnershipis a significant step in delivering advanced cancer therapies to patients who need them themost and ensuring equitable access to high-quality biosimilars in low- and middle-incomecountries (LMICs), Biocon Biologics said in a statement.
Biocon Biologics willinitially supply biosimilar Trastuzumab and biosimilar Pegfilgrastim and will expand the arrangement to includeother biosimilars,it added. Biocon Biologics Executive ChairpersonKiran Mazumdar-Shaw said, The collaboration with CHAI further strengthens our resolve to address the unmet patient needs in Asia and Africa for advanced cancer therapies through cost effective alternatives to expensive reference biologics.
Thursday, 04 Feb 2021 08:12 AM MYT
TB ― a respiratory disease that is preventable and treatable yet kills more than 1.4 million people every year ― is chronically underfunded, with diagnosis and treatment failing to reach millions. ― ETX Studio pic
Subscribe to our Telegram channel for the latest updates on news you need to know.
GENEVA, Feb 4 ― A new tuberculosis treatment that slashes costs and the pill burden for patients will be rolled out in five high-incidence countries this year, international medical research body the Aurum Institute said yesterday.
TB ― a respiratory disease that is preventable and treatable yet kills more than 1.4 million people every year ― is chronically underfunded, with diagnosis and treatment failing to reach millions.
Biocon arm, CHAI in pact on affordable cancer therapies
Updated:
Updated:
Share Article
AAA
Biocon Biologics, a pure-play biosimilars firm and subsidiary of Biocon Ltd., has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to life-saving cancer biosimilars in more than 30 countries in Africa and Asia, as part of the Cancer Access Partnership (CAP).
As per the agreement, Biocon Biologics would aim to deliver affordable biosimilar cancer therapies in 25 countries in Africa and five countries in Asia, currently covered under CAP, led by the CHAI.
The company would initially supply bTrastuzumab and bPegfilgrastim and expand the arrangement to include other biosimilars.
New TB treatment to cut pill intake by two-thirds: study AFP, Johannesburg AFP, Johannesburg
A new tuberculosis treatment that slashes costs and the pill burden for patients will be rolled out in five high-incidence countries this year, international medical research body the Aurum Institute said yesterday.
TB a respiratory disease that is preventable and treatable yet kills more than 1.4 million people every year is chronically underfunded, with diagnosis and treatment failing to reach millions.
It is currently the world s deadliest infectious disease, with progress to stop its spread unwound by the Covid-19 pandemic as restricted movement disrupted treatment.